

Global Benign Prostatic Hyperplasia Treatment Market Outlook 2025-2034: Growth Drivers, Share, And Trends

The Business Research Company's Benign Prostatic Hyperplasia Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034

LONDON, GREATER LONDON, UNITED KINGDOM, March 24, 2025

[/Einpresswire.com/](https://www.einpresswire.com/) -- The [benign prostatic hyperplasia treatment market](#)

has seen impressive growth in recent years. Will this trend continue?



Currently at a size of \$8.23 billion in 2024, the global market for benign prostatic hyperplasia treatment is projected to grow to \$8.71 billion in 2025, at a compound annual growth rate CAGR of 5.9%. The primary factors fuelling this growth include growing awareness and screening initiatives, rising prevalence of BPH, increasing healthcare awareness, improving healthcare infrastructure, and a growing elderly population.



Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

”

The Business Research Company

What is driving the growth of the benign prostatic hyperplasia treatment market?

The rise in adoption of minimally invasive surgeries is expected to propel the growth of the benign prostatic

hyperplasia treatment market moving forward. These surgeries, using small or no incisions and specialized instruments, offer reduced recovery time, pain, and risk of complications. For much-needed symptom relief, BPH treatment through these surgeries provides patients with reduced recovery times and lower risks of complications. According to a report by the American Society of Plastic Surgeons ASPS, a total of 23,672,269 cosmetic minimally invasive procedures were performed globally in 2022, attesting to the growing trend of these procedures.

The BPH treatment market is expected to continue its strong trajectory of growth in the imminent future. It is estimated to reach \$10.83 billion in 2029, at a compound annual growth

rate CAGR of 5.6%. Market trends in the forecast period will most likely revolve around targeted therapies, the integration of digital health solutions, surgical innovations, 3D imaging for diagnosis, and patient-centered care models.

Get Your Free Sample Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=21112&type=smp>

Which companies are leading the benign prostatic hyperplasia treatment market?

Key companies driving the market include Pfizer Inc., Merck And Co Inc, AbbVie Inc., Bayer AG, Sanofi S.A., GlaxoSmithKline Public Limited Company, Medtronic Public Limited Company, Mezzion Pharma Co Ltd, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Boston Scientific Corporation, Astellas Pharma Inc., Olympus Corporation, Coloplast Group, Teleflex Incorporated, Cook Medical Incorporated, AngioDynamics, Inc., HistoSonics Inc, Urovant Sciences Ltd, UroGen Pharma Ltd., Urologix Inc, Zenflow Inc, Butterfly Medical Ltd. These industry leaders are prioritizing innovative solutions, focusing on the development of minimally invasive procedures.

How is the benign prostatic hyperplasia treatment market segmented?

The market is segmented by Treatment into Minimal Invasive Surgery and Invasive Surgery; by Therapeutic Class into Alpha Blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Other Therapeutic Classes; and by End User into Home Healthcare, Hospitals And Clinics, Research And Manufacturing facilities.

Order Your Report Now For A Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/benign-prostatic-hyperplasia-treatment-global-market-report>

What is the regional outlook of the benign prostatic hyperplasia treatment market?

On a regional scale, North America was the largest in the BPH treatment market in 2024. Looking forward, Asia-Pacific is predicted to be the fastest-growing region for this market. Other regions evaluated in the [benign prostatic hyperplasia treatment market report](#) are Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Find more similar reports by [The Business Research Company](#).

Prostate Cancer Drugs Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report>

Drugs for Immunotherapy Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/drugs-for-immunotherapy-global->

[market-report](#)

Genito-Urinary Drugs Global Market Report 2022

<https://www.thebusinessresearchcompany.com/report/genito-urinary-drugs-global-market-report>

With an access to over 15000+ prudent reports across 27 industries covering over 60+ geographies, The Business Research Company enables you to stay ahead in the game with its comprehensive, data-rich research and bespoke insights. The company's 1,500,000 datasets, optimistic contribution of in-depth secondary research, and unique insights from industry leaders deliver the business intelligence you need to make informed decisions.

Connect with The Business Research Company:

Website: <https://www.thebusinessresearchcompany.com/>

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email: info@tbrc.info

Stay updated with us:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

YouTube: https://www.youtube.com/channel/UC24_f10rV8cR5DxICpgmyFQ

Global Market Model: <https://www.thebusinessresearchcompany.com/global-market-model>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/796554283>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.